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introduction: In Egypt, disorders of sex development (DSD) constitute a 
significant entity among the birth defect list. Previous studies have reported that 
end organ androgen unresponsiveness, i.e. Androgen resistance, was the most 
prevalent underlying mechanism among Egyptian 46,XY DSD cases. Based 
on cytogenetic and hormonal diagnostic criteria as well as few sporadic case 
reports, it was proposed that androgen receptor (AR) defects [i.e. Androgen 
insensitivity syndrome (AIS), OMIM#300068] might constitute a major etiology 
within this category. However, this has never been systematically ascertained 
through an AR molecular diagnostic approach. 
aim of the Work: The current study aimed to assess the role of AR mutations 
as an underlying etiology among a sample of Egyptian 46,XY DSD pediatric 
patients presenting with androgen end organ unresponsiveness.
Patients and Method: In the current study, 21 children [age<18years] with 
male undermasculinization due to androgen end organ unresponsiveness were 
selected from 46,XY DSD cases. The selection criteria included ambiguous 
genital phenotype or genitalia discordant to the genotypic sex; 46,XY Karyotype 
and normal testicular response to HCG stimulation in prepubertal patients 
or normal basal testosterone (T) levels in postpubertal subjects. Molecular 
studies of the AR entailed PCR amplification for screening of major deletions/
insertions, single stranded conformational polymorphism (SSCP) screening for 
point mutations in the AR 2-8 exons followed by sequencing of these exons for 
all cases.
results: The results showed that none had major deletions/insertions. Five 
exons out of 147 (3.4%) showed abnormal SSCP migrational patterns. Out of 
those 5, two mutations in two Egyptian patients were detected by sequencing. 
The first was R840G (Arginine 840 glycine), in exon 7 (The ligand binding 
domain). The other was A596T (Alanine 596 Threonine) in exon 3 (The DNA 
binding domain). 
conclusion:, This study shows that AR mutation is an uncommon underlying 
etiology among Egyptian paediatric 46,XY cases.
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introduction                                                                     
In Egypt, disorders of sex develop-
ment (DSD) constitute a significant en-
tity among the birth defect list, where 
their incidence reaches 1 in 3000 live 
births.1 Previous studies have reported 
that end organ androgen unresponsive-
ness, i.e. Androgen resistance, was the 
most prevalent underlying mechanism 
among Egyptian 46,XY cases.2-4 Based 
on cytogenetic and hormonal diagnostic 
criteria, it has been proposed that an-
drogen receptor (AR) defects [i.e. An-
drogen insensitivity syndrome (AIS), 
OMIM#300068] might constitute a 
major etiology in this category, in addi-
tion to the deficiency of 5 α-reductase 2 
(5αR2) enzyme.2-5
The AR is a ligand-activated transcrip-
tion factor required for male sex devel-
opment and virilization. High affinity an-
drogen binding triggers conformational 
changes required for AR transactiva-
tion.6 The two major androgens, testos-
terone (T) and 5α-dihydrotestosterone 
(DHT), both act through the AR, which 
is encoded by a single-copy gene located 
at chromosome band Xq11.2-q12. The 
complete sequence of the human AR 
cDNA is 3.6 Kbp. It contains an open 
reading frame of 2757 bp encoding 919 
amino acids. The human AR consists of 
the N-terminal transactivation domain 
(1–538), DNA-binding domain (DBD) 
(539–627), hinge region (628–644), 
and C-terminal ligand-binding domain 
(LBD) (645–919).7
Mutations in the AR gene cause a broad 
spectrum of abnormal phenotypes in 
humans, ranging from infertility in an 
otherwise normal male (Mild AIS), to 
ambiguous genitalia (Partial AIS), to a 
completely female external phenotype 
[Complete AIS (CAIS)].8 The diagnosis 
of AIS is provisionally inferred from 
clinical and biochemical findings: a 46 
XY karyotype, absence of Mullerian-
derived structures, normal testicular 
histology, and age-appropriate andro-
gen production by the testis.
More than 700 mutations in the AR 
gene have now been document-
ed in AIS [http://www.mcgill.ca/
androgendb/24/7/2007]. A number of 
reports have reported on single cases of 
AR mutations among Egyptian 46, XY 
DSD patients.9-12 The current study em-
ployed a systematic molecular approach 
towards assessing the role of AR muta-
tions as an underlying etiology among 
a sample of Egyptian 46,XY pediatric 
patients presenting with androgen end 
organ unresponsiveness.
PatientS and MethodS                                     
Patients:
Over a period of two years, 21 children 
[age<18years] with male undermascu-
linization due to androgen end organ 
unresponsiveness were selected from 
the DSD cases presenting to the divi-
sion of Human Genetics and Genome 
Research, National Research Center 
(NRC).
The selection criteria for the patients 
included ambiguous genital phenotype 
or genitalia discordant to the genotypic 
sex, 46,XY Karyotype and normal tes-
ticular response to HCG stimulation in 
prepubertal patients or normal basal T 




Molecular analysis of AR gene
Extraction:1.  genomic DNA was ex-
tracted from peripheral blood lym-
phocytes of all patients by salting 
out technique13 with some modifi-
cations.
Screening for major deletions or 2. 
insertions: Exons 2-8 (Or B-H) 
of the AR gene were amplified by 
PCR using intron specific primers.14 
One hundred ng of DNA was used 
in amplification buffer containing 
50mM KCl, 10mM tris HCl pH 
8.3, 1.5mM Mg Cl2, 20μM dNTP, 
0.2μM each primer and Taq poly-
merase1 (Unit/reaction) (Promega). 
Amplification conditions consisted 
of 35 cycles, each consists of dena-
turing at 94ºC for 75 seconds, an-
nealing (At 52ºC for exon B, 53ºC 
for exon C, 50ºC for exon D, 64ºC 
for exon E, 60ºC for exon F, 64ºC 
for exon G and 55ºC for exon H) for 
90 seconds, and extension at 72ºC 
for 2min. The amplified products 
were visualized by Ethidium bro-
mide on 1-2% Agarose gel electro-
phoresis.
Screening for point mutations us-3. 
ing SSCP technique: SSCP analy-
sis is based on the principle that “A 
single base change between PCR 
products, which are amplified using 
the same primers, is sufficient to al-
ter the mobility of single stranded 
products when electrophoresed 
through non-denaturing polyacryl-
amide gel”.15 
In PCR-SSCP analysis, amplified 
double-stranded products were heat 
denatured and prevented from rean-
nealing to its complement   strand 
by cooling, and by the addition 
of formamide (As a denaturating 
agent). PCR products were prepared 
by adding 15 ul formamide loading 
buffer to 4 ul of the PCR products 
then denatured at 95ºC for 10 min, 
and immediately dipped in ice for 5 
min before loading on 10% of non-
denaturing polyacrylamide gel. The 
samples were loaded and run at 400 
V for 3 hours at 7º C.
Silver staining of the SSCP gel: To 
stain the SSCP gel, Silver Sequence 
TM DNA Sequencing System, 
(Promega, USA) was used. The gel 
was put in saran wrap then viewed 
on a light box to visualize bands 
migration.
Sequencing reaction:4.  The ampli-
fied DNA products were purified 
using Centricon microconcentra-
tors (Amicon, Beverly, MA 01915, 
USA). The purified PCR products 
were dried and resuspended in buf-
fer (20mM MgCL2, 50mM NaCL, 
40µM Tris, pH 7.5) and 2µM se-
quencing primer, in a total  volume 
of 10µl After annealing at 65ºC 
for 2 minutes, dideoxy sequenc-
ing was performed  using  the se-
quence V.2 Kit (US Biochemical 
Corp. Cleveland, OH 44122,USA). 
The sequencing analysis was done 
using ABI Prism Dye terminator 
sequencing kit and the ABI 310 ge-
netic analyzer apparatus (Applied 
Biosystems).
reSultS                                                                     
The age of the studied cases ranged 
from 0.5-17.9 years. Eleven cases were 
reared as males and 10 as females. Pa-
rental consanguinity was noticed in 17 
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out of the 21 cases, (81%). All patients 
had a 46,XY karyotype.
The T levels in the 4 post pubertal sub-
jects ranged from 2.7-16 ng/ml, while 
in the prepubertal subjects, the post-
HCG levels reached 2.2-16 ng/ml. The 
values of the  postpubertal  basal  and 
prepubertal post-HCG T/DHT  ratios 
varied from 6.2-98.5. Compared to our 
normal range2, abnormally increased T/
DHT values (i.e.>14) were noticed in 
17 out of 21 cases (81%).
Molecular data:
Screening for major deletions or 1. 
insertions in the AR gene: Using 
PCR amplification of individual ex-
ons (2-8) of the AR gene, no major 
deletions or insertions were noted 
in any of the 21 studied cases.
Screening for point mutations in 2. 
the AR gene: SSCP analysis for in-
dividual exons of AR gene was done 
as mentioned before. Four cases out 
of 21 (19%) showed changes in the 
migration patterns  of five exons 
{Exon 7 (G), in case no. 18, exon 
5 (E), in case no. 19, exon 3 (C), in 
case no. 20 Figure (1), and exons 5 
(E) and 7 (G) in case  no. 21}.
                  1                       2                       3             
Fig. 1: SSCP analysis of exon C of AR gene: 
Lane 1 represents SSCP analysis of exon C of 
case no. 20 that displayed a change in electro-
phoretic migration pattern in respect to the nor-
mal controls (Lanes 1&2).
Fig. 2: Sequencing analysis of exon G in patient no. 18 with R840G mutation. 
The patient (right panel) shows change in the first base of codon 840 leading to   change of that codon 
from CGT (arginine) to GGT (Glycine).The left panel shows the normal sequence.
Sequencing of the AR gene:3.  Se-
quencing of the 2-8 exons for all 
cases was carried out. A missense 
point mutation was detected in 
exon 7 of patient no. 18 (Figure 2) 
where the arginine residue (R) at 
codon 840 was replaced by glycine 
(G) (R840G).
control  r840 Patient  g840
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Another missense point mutation 
was detected in exon 3 in patient 
no. 19 (Figure 3) where alanine res-
idue (A) at codon 569 was replaced 
by threonine (T) (A569T).
On the other hand, the other 3 exons 
that showed abnormal SSCP migra-
tional patterns proved to have no 
mutations using sequencing of both 
the forward and reverse strands.
Fig. 3: Sequencing analysis of exon C in patient no. 20 with A596T mutation.
The patient (Right panel) shows change in the first base of codon 596 leading to change of that codon 
from GCC (Alanine) to ACC (Threonine).The left panel shows the normal sequence.
 control   a 596  Patient   t 596
diScuSSion                                                                     
Abnormal sexual development is not 
uncommon in Egypt. A study reported 
an incidence of one newborn with am-
biguous genitalia per 3000 live births.1 
Another study showed that 46, XY 
DSD owing to androgen resistance con-
stituted ~25% of DSD presentations in 
Egyptian patients.4 This makes it one 
of the two most common etiologies un-
derlying 46,XY DSD states in Egyptian 
patients, in addition to 21-hydroxylase 
deficiency in 46,XX patients.
In the present study, a sample of patients 
(21 cases) presenting with 46,XY DSD 
due to androgen resistance was studied, 
aiming to evaluate the relative signifi-
cance of AR mutations as an underly-
ing etiology. The study comprised three 
main stages, the  clinical phenotype as-
sessment, the biochemical or hormonal 
evaluations and lastly the molecular de-
tection of AR gene mutations.
The clinical presentation of all studied 
patients generally entailed ambiguous 
genitalia. However, the degree of am-
biguity was variable from one case to 
another. The study showed that the ex-
ternal genital phenotypes varied from 
female to ambiguous to nearly male 
genitalia (Data not shown). This re-
flected the wide range of phenotypic 
heterogeneity in androgen resistance 
disorders. 
Parental consanguinity was noted in 17 
out of 21 patients (81%). This high fre-
quency  is much higher than the average 
parental consanguinity rate among the 
Egyptian general population which is 
nearly 1/3.1 Androgen resistance entails 
several genetic defects (i.e.5αR2D, AR 
defects or post AR defects).16 The pres-
ence of high inbreeding rate in the pa-
tient groups may provisionally infer the 
relevance  of autosomal recessive DSD 
form(s) and undermine the possibility 
of AR defects as a prevalent underlying 
Androgen Receptor Mutation in Egyptian 46,XY DSD 
116
etiology. Androgen resistance is com-
monly reported as a monogenic disease 
resulting from mutations in either SR-
D5A2 or AR genes.17-21 Moreover, all 
patients presented with genital ambigu-
ity as an isolated anomaly conforming 
with the notion that DSD in general are 
scarcely reported as a part of multiple 
congenital anomaly syndrome.4,12
general analysis of the patients, 
molecular data showed a number of 
findings: 
First, there ware no major dele-
tions or insertions in any of the pa-
tients. This conforms with the very 
low frequency of such genetic events 
worldwide (AR mutation database, 
http://www.mcgill.ca/androgendb/).
Second, the mutation rate in exons 
2-8    of the AR gene was low among 
the studied groups (i.e. only 2/21, or 
9.5%). Several explanations can be 
postulated in this regard. Firstly, Exon 
1 was not analysed in the studied cas-
es due to technical reasons but could 
harbor an underlying mutation. A sec-
ond possibility entails a prevalence of 
5αR2D among the patient sample. This 
disorder has been frequently reported 
among Egyptian DSD patients.2,4,5,9,20,21 
Thirdly, the criteria for selecting the 
cases focused on patients presented 
with ambiguous genitalia that mani-
fested in infancy and childhood. That 
is in contrast with cases with complete 
testicular feminization who usually do 
not present in that age as they usually 
have a typical female phenotype (i.e. 
female external genitalia).22 Moreover, 
at puberty subjects with complete AIS 
have excellent feminization resulting 
from high estrogen levels due to testic-
ular estrogen secretion and peripheral 
aromatization of T. As a result, most of 
those cases are seeking clinical advice 
for causes of primary amenorrhea and 
delayed puberty at the time of puberty 
in gynecologic clinics.
Third, there was some discordance be-
tween the numbers of cases showing 
altered SSCP migrational patterns and 
those documented to have a mutation by 
sequencing analysis. Out of 147 analy-
ses, 5 exons showed abnormal migra-
tion, two of them had a mutation. Thus, 
there were no false negatives (0/147, 
0%), but 3/147, or 2% were false posi-
tive. This points out that SSCP may be 
a valid and sensitive screening tool for 
AR mutation detection but it still has 
some limitations regarding the assay 
specificity.
Among the patient sample, the 2 de-
tected mutations comprised A596T 
and R840G. The A596T mutation was 
previously reported four times in cases 
with Reifenstein syndrome23, somatic 
mosaicism24, PAI25 and ambiguous gen-
italia.26 Although these patients were 
carrying the same mutation, they were 
presenting with different clinical phe-
notypes, suggesting variability in the 
expression of the same mutation in un-
related patients.
The mutation, A to T, on exon 3 re-
placed alanine to threonine at position 
596 within the receptor DBD which 
makes up the D-loop of the receptor. 
The D-loop and sequences in the hor-
mone binding domain together provide 
the interacting surfaces for receptor di-
mer formation and subsequent binding 
to DNA. It was demonstrated that the 
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destruction of dimerization of the AR 
is one of the causes of Reifenstein syn-
drome.23
The R840G mutation was characterized 
in another case in exon 7 of the AR-
LBD. This mutation has been reported 
only once.25 Three other mutations 
of the same residue (R840S; R840C, 
nonconservative; and R840H, conser-
vative) have been reported in patients 
with PAIS. Each of these mutations was 
associated with a very diverse spectrum 
of phenotypes. These data highlight the 
role of the AR ligand-binding pocket 
(LBP) in the expression of transcrip-
tional activity during prenatal sex dif-
ferentiation. Four sites in the steroid-
binding domain, arginine residues 774, 
840, and 855, and valine 866, appear to 
have a particularly high frequency of 
mutation and together account for about 
one quarter of the missense mutations 
reported to date.27
The provisional diagnosis of AIS is 
usually supported by a normal T/DHT 
ratio. However, variable T/DHT values 
have also been observed among pa-
tients, depending on the patient’s age 
and the HCG stimulation procedures.28
Moreover, 5αRD secondary to AR de-
fects resulting in high T/DHT values 
have been reported and made diagno-
sis more difficult.19 This has been il-
lustrated in the current study where the 
R840G carrying patient had normal T/
DHT ration [6.2], while the other hav-
ing A596T showed a 50.7 T/DHT val-
ue. This reconfirms the notion that the 
molecular analysis remains the only 
definitive tool for diagnosis of AR de-
fects, which were showed to be an un-
common finding among Egyptian Pedi-
atric 46,XY DSD cases presenting with 
androgen endorgan unresponsiveness.
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